Andrew Berens
Stock Analyst at Leerink Partners
(2.36)
# 2,422
Out of 5,182 analysts
98
Total ratings
47.56%
Success rate
-1.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Berens
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZYME Zymeworks | Maintains: Outperform | $52 → $58 | $28.56 | +103.08% | 11 | Mar 3, 2026 | |
| IMRX Immuneering | Initiates: Outperform | $15 | $5.76 | +160.42% | 1 | Oct 31, 2025 | |
| COGT Cogent Biosciences | Maintains: Outperform | $18 → $20 | $36.61 | -45.36% | 6 | Jan 5, 2023 | |
| RLMD Relmada Therapeutics | Upgrades: Outperform | $8 | $7.03 | +13.80% | 1 | Jan 23, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Outperform | $34 → $40 | $24.43 | +63.73% | 13 | Dec 26, 2025 | |
| NUVL Nuvalent | Maintains: Outperform | $140 → $149 | $104.04 | +43.21% | 3 | Nov 17, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Initiates: Outperform | $25 | $8.79 | +184.41% | 1 | Sep 17, 2025 | |
| CELC Celcuity | Maintains: Outperform | $28 → $60 | $125.68 | -52.26% | 2 | Jul 28, 2025 | |
| ARVN Arvinas | Downgrades: Market Perform | $10 → $9 | $10.29 | -12.54% | 6 | Jun 2, 2025 | |
| CMPX Compass Therapeutics | Upgrades: Outperform | $4 → $6 | $1.79 | +235.20% | 3 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $880 → $762 | $744.44 | +2.36% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $4.99 | +561.32% | 1 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $74 → $96 | $127.75 | -24.85% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $78 | $95.72 | -18.51% | 12 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $28 | $16.49 | +69.80% | 3 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $79 | $187.51 | -57.87% | 12 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $27 | $4.25 | +535.29% | 7 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $25 | $13.25 | +88.68% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $6.96 | +474.71% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $67 | $2.83 | +2,267.49% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $20 | $19.29 | +3.68% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $26.33 | -5.05% | 1 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $8 | $9.52 | -15.97% | 7 | Jul 14, 2017 |
Zymeworks
Mar 3, 2026
Maintains: Outperform
Price Target: $52 → $58
Current: $28.56
Upside: +103.08%
Immuneering
Oct 31, 2025
Initiates: Outperform
Price Target: $15
Current: $5.76
Upside: +160.42%
Cogent Biosciences
Jan 5, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $36.61
Upside: -45.36%
Relmada Therapeutics
Jan 23, 2026
Upgrades: Outperform
Price Target: $8
Current: $7.03
Upside: +13.80%
Agios Pharmaceuticals
Dec 26, 2025
Maintains: Outperform
Price Target: $34 → $40
Current: $24.43
Upside: +63.73%
Nuvalent
Nov 17, 2025
Maintains: Outperform
Price Target: $140 → $149
Current: $104.04
Upside: +43.21%
BridgeBio Oncology Therapeutics
Sep 17, 2025
Initiates: Outperform
Price Target: $25
Current: $8.79
Upside: +184.41%
Celcuity
Jul 28, 2025
Maintains: Outperform
Price Target: $28 → $60
Current: $125.68
Upside: -52.26%
Arvinas
Jun 2, 2025
Downgrades: Market Perform
Price Target: $10 → $9
Current: $10.29
Upside: -12.54%
Compass Therapeutics
Apr 2, 2025
Upgrades: Outperform
Price Target: $4 → $6
Current: $1.79
Upside: +235.20%
Jan 28, 2025
Maintains: Market Perform
Price Target: $880 → $762
Current: $744.44
Upside: +2.36%
Dec 5, 2024
Initiates: Outperform
Price Target: $33
Current: $4.99
Upside: +561.32%
Oct 21, 2024
Upgrades: Outperform
Price Target: $74 → $96
Current: $127.75
Upside: -24.85%
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $95.72
Upside: -18.51%
Dec 13, 2022
Maintains: Outperform
Price Target: $37 → $28
Current: $16.49
Upside: +69.80%
Nov 14, 2022
Maintains: Outperform
Price Target: $78 → $79
Current: $187.51
Upside: -57.87%
Nov 10, 2022
Maintains: Outperform
Price Target: $42 → $27
Current: $4.25
Upside: +535.29%
May 13, 2022
Maintains: Outperform
Price Target: $36 → $25
Current: $13.25
Upside: +88.68%
Nov 23, 2021
Initiates: Outperform
Price Target: $40
Current: $6.96
Upside: +474.71%
Oct 14, 2021
Initiates: Outperform
Price Target: $67
Current: $2.83
Upside: +2,267.49%
Oct 14, 2021
Initiates: Market Perform
Price Target: $20
Current: $19.29
Upside: +3.68%
Sep 20, 2021
Initiates: Outperform
Price Target: $25
Current: $26.33
Upside: -5.05%
Jul 14, 2017
Maintains: Equal-Weight
Price Target: $16 → $8
Current: $9.52
Upside: -15.97%